215 related articles for article (PubMed ID: 22730530)
1. Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain.
Takezaki S; Yamada M; Kato M; Park MJ; Maruyama K; Yamazaki Y; Chida N; Ohara O; Kobayashi I; Ariga T
J Immunol; 2012 Aug; 189(3):1521-6. PubMed ID: 22730530
[TBL] [Abstract][Full Text] [Related]
2. Two novel gain-of-function mutations of STAT1 responsible for chronic mucocutaneous candidiasis disease: impaired production of IL-17A and IL-22, and the presence of anti-IL-17F autoantibody.
Yamazaki Y; Yamada M; Kawai T; Morio T; Onodera M; Ueki M; Watanabe N; Takada H; Takezaki S; Chida N; Kobayashi I; Ariga T
J Immunol; 2014 Nov; 193(10):4880-7. PubMed ID: 25288569
[TBL] [Abstract][Full Text] [Related]
3. New and recurrent gain-of-function STAT1 mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe.
Soltész B; Tóth B; Shabashova N; Bondarenko A; Okada S; Cypowyj S; Abhyankar A; Csorba G; Taskó S; Sarkadi AK; Méhes L; Rozsíval P; Neumann D; Chernyshova L; Tulassay Z; Puel A; Casanova JL; Sediva A; Litzman J; Maródi L
J Med Genet; 2013 Sep; 50(9):567-78. PubMed ID: 23709754
[TBL] [Abstract][Full Text] [Related]
4. The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1.
Depner M; Fuchs S; Raabe J; Frede N; Glocker C; Doffinger R; Gkrania-Klotsas E; Kumararatne D; Atkinson TP; Schroeder HW; Niehues T; Dückers G; Stray-Pedersen A; Baumann U; Schmidt R; Franco JL; Orrego J; Ben-Shoshan M; McCusker C; Jacob CM; Carneiro-Sampaio M; Devlin LA; Edgar JD; Henderson P; Russell RK; Skytte AB; Seneviratne SL; Wanders J; Stauss H; Meyts I; Moens L; Jesenak M; Kobbe R; Borte S; Borte M; Wright DA; Hagin D; Torgerson TR; Grimbacher B
J Clin Immunol; 2016 Jan; 36(1):73-84. PubMed ID: 26604104
[TBL] [Abstract][Full Text] [Related]
5. A novel gain-of-function STAT1 mutation resulting in basal phosphorylation of STAT1 and increased distal IFN-γ-mediated responses in chronic mucocutaneous candidiasis.
Martinez-Martinez L; Martinez-Saavedra MT; Fuentes-Prior P; Barnadas M; Rubiales MV; Noda J; Badell I; Rodríguez-Gallego C; de la Calle-Martin O
Mol Immunol; 2015 Dec; 68(2 Pt C):597-605. PubMed ID: 26514428
[TBL] [Abstract][Full Text] [Related]
6. Functional analysis of two STAT1 gain-of-function mutations in two Iranian families with autosomal dominant chronic mucocutaneous candidiasis.
Ostadi V; Sherkat R; Migaud M; Modaressadeghi SM; Casanova JL; Puel A; Nekooie-Marnany N; Ganjalikhani-Hakemi M
Med Mycol; 2021 Feb; 59(2):180-188. PubMed ID: 32526033
[TBL] [Abstract][Full Text] [Related]
7. Recurrent, Severe Aphthous Stomatitis and Mucosal Ulcers as Primary Manifestations of a Novel
Erdős M; Jakobicz E; Soltész B; Tóth B; Bata-Csörgő Z; Maródi L
Front Immunol; 2020; 11():967. PubMed ID: 32547544
[TBL] [Abstract][Full Text] [Related]
8. Chinese Pedigree of Chronic Mucocutaneous Candidiasis Due to STAT1 Gain-of-Function Mutation: A Case Study and Literature Review.
Wang X; Zhao W; Chen F; Zhou P; Yan Z
Mycopathologia; 2023 Apr; 188(1-2):87-97. PubMed ID: 36335528
[TBL] [Abstract][Full Text] [Related]
9. Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC).
Zheng J; van de Veerdonk FL; Crossland KL; Smeekens SP; Chan CM; Al Shehri T; Abinun M; Gennery AR; Mann J; Lendrem DW; Netea MG; Rowan AD; Lilic D
Eur J Immunol; 2015 Oct; 45(10):2834-46. PubMed ID: 26255980
[TBL] [Abstract][Full Text] [Related]
10. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis.
van de Veerdonk FL; Plantinga TS; Hoischen A; Smeekens SP; Joosten LA; Gilissen C; Arts P; Rosentul DC; Carmichael AJ; Smits-van der Graaf CA; Kullberg BJ; van der Meer JW; Lilic D; Veltman JA; Netea MG
N Engl J Med; 2011 Jul; 365(1):54-61. PubMed ID: 21714643
[TBL] [Abstract][Full Text] [Related]
11. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis.
Liu L; Okada S; Kong XF; Kreins AY; Cypowyj S; Abhyankar A; Toubiana J; Itan Y; Audry M; Nitschke P; Masson C; Toth B; Flatot J; Migaud M; Chrabieh M; Kochetkov T; Bolze A; Borghesi A; Toulon A; Hiller J; Eyerich S; Eyerich K; Gulácsy V; Chernyshova L; Chernyshov V; Bondarenko A; Grimaldo RM; Blancas-Galicia L; Beas IM; Roesler J; Magdorf K; Engelhard D; Thumerelle C; Burgel PR; Hoernes M; Drexel B; Seger R; Kusuma T; Jansson AF; Sawalle-Belohradsky J; Belohradsky B; Jouanguy E; Bustamante J; Bué M; Karin N; Wildbaum G; Bodemer C; Lortholary O; Fischer A; Blanche S; Al-Muhsen S; Reichenbach J; Kobayashi M; Rosales FE; Lozano CT; Kilic SS; Oleastro M; Etzioni A; Traidl-Hoffmann C; Renner ED; Abel L; Picard C; Maródi L; Boisson-Dupuis S; Puel A; Casanova JL
J Exp Med; 2011 Aug; 208(8):1635-48. PubMed ID: 21727188
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Disseminated
Chen K; Tan J; Qian S; Wu S; Chen Q
Front Immunol; 2021; 12():682350. PubMed ID: 34421897
[TBL] [Abstract][Full Text] [Related]
13. Chronic mucocutaneous candidiasis due to gain-of-function mutation in STAT1.
Carey B; Lambourne J; Porter S; Hodgson T
Oral Dis; 2019 Apr; 25(3):684-692. PubMed ID: 29702748
[TBL] [Abstract][Full Text] [Related]
14. Identification of a distinct subset of disease-associated gain-of-function missense mutations in the STAT1 coiled-coil domain as system mutants.
Petersen J; Staab J; Bader O; Buhl T; Ivetic A; Meyer T
Mol Immunol; 2019 Oct; 114():30-40. PubMed ID: 31336247
[TBL] [Abstract][Full Text] [Related]
15. Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations.
Tabellini G; Vairo D; Scomodon O; Tamassia N; Ferraro RM; Patrizi O; Gasperini S; Soresina A; Giardino G; Pignata C; Lougaris V; Plebani A; Dotta L; Cassatella MA; Parolini S; Badolato R
J Allergy Clin Immunol; 2017 Aug; 140(2):553-564.e4. PubMed ID: 28069426
[TBL] [Abstract][Full Text] [Related]
16. A gain-of-function mutation of STAT1: A novel genetic factor contributing to chronic mucocutaneous candidiasis.
Eslami N; Tavakol M; Mesdaghi M; Gharegozlou M; Casanova JL; Puel A; Okada S; Arshi S; Bemanian MH; Fallahpour M; Molatefi R; Seif F; Zoghi S; Rezaei N; Nabavi M
Acta Microbiol Immunol Hung; 2017 Jun; 64(2):191-201. PubMed ID: 28597685
[TBL] [Abstract][Full Text] [Related]
17. Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation.
Bloomfield M; Kanderová V; Paračková Z; Vrabcová P; Svatoň M; Froňková E; Fejtková M; Zachová R; Rataj M; Zentsová I; Milota T; Klocperk A; Kalina T; Šedivá A
J Clin Immunol; 2018 Jul; 38(5):589-601. PubMed ID: 29934865
[TBL] [Abstract][Full Text] [Related]
18. Treatment options for chronic mucocutaneous candidiasis.
van de Veerdonk FL; Netea MG
J Infect; 2016 Jul; 72 Suppl():S56-60. PubMed ID: 27161991
[TBL] [Abstract][Full Text] [Related]
19. Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy.
Okada S; Asano T; Moriya K; Boisson-Dupuis S; Kobayashi M; Casanova JL; Puel A
J Clin Immunol; 2020 Nov; 40(8):1065-1081. PubMed ID: 32852681
[TBL] [Abstract][Full Text] [Related]
20. STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis.
Smeekens SP; Plantinga TS; van de Veerdonk FL; Heinhuis B; Hoischen A; Joosten LA; Arkwright PD; Gennery A; Kullberg BJ; Veltman JA; Lilic D; van der Meer JW; Netea MG
PLoS One; 2011; 6(12):e29248. PubMed ID: 22195034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
